Vraylar vs. Geodon

See how Vraylar and Geodon compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Vraylar is approved for four conditions, including bipolar depression and add-on treatment for major depressive disorder, while Geodon is approved mainly for schizophrenia and bipolar mania.

  • Geodon carries a stronger QT-prolongation warning and must be taken with a substantial meal, while Vraylar has no specific heart-rhythm warning and works with or without food.

  • Vraylar is a newer, brand-only drug with no generic version yet, while Geodon has been available as a lower-cost generic for years.

Vraylar vs. Geodon Drug Summary

Vraylar

Vraylar (cariprazine) is an atypical antipsychotic approved for schizophrenia in adults and teens 13 and older, and for all phases of bipolar I disorder, from manic episodes to depression. It is also approved as an add-on to antidepressants for major depressive disorder, and is taken as a once-daily capsule with or without food.

Geodon

Geodon (ziprasidone) is an atypical antipsychotic approved for schizophrenia and for acute manic or mixed episodes of bipolar disorder, either alone or combined with lithium or valproate for maintenance. It is taken as a twice-daily oral capsule with food, and is also available as a short-term injection for acute agitation.

Vraylar vs. Geodon Side Effects

Vraylar

Most common
Extrapyramidal symptoms (up to 19%)
Akathisia (up to 13%)
Dizziness (up to 5%)
Increased appetite (up to 5%)

Geodon

Most common
Extrapyramidal symptoms (up to 31%)
Somnolence (14-20%)
Headache (13-18%)
Nausea (up to 12%)

Vraylar vs. Geodon Dosage

Vraylar

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1.5 mg once daily Day 1
Maximum dose 6 mg once daily If needed
Dose changes 4 increases Every day

Geodon

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 20 mg twice daily At the start
Maximum dose 20-80 mg twice daily If needed
Dose changes 1 increase As tolerated

Vraylar vs. Geodon Indications

Vraylar

Vraylar treats schizophrenia in adults and adolescents 13 and older, and covers every phase of bipolar I disorder, from manic and mixed episodes to depression. It is also FDA-approved as an add-on to antidepressants for major depressive disorder in adults, giving it one of the broadest approval profiles among newer antipsychotics.

  • Schizophrenia, ages 13 and up

  • Bipolar I manic or mixed episodes, ages 10+

  • Bipolar I depression, adults

  • Adjunctive treatment for major depressive disorder, adults

Geodon

Geodon treats schizophrenia in adults and manages acute manic or mixed episodes of bipolar I disorder, either on its own or alongside lithium or valproate for ongoing maintenance. A short-term injectable form is also approved for acute agitation in people with schizophrenia.

  • Schizophrenia, adults

  • Acute bipolar manic or mixed episodes (monotherapy)

  • Bipolar disorder maintenance, with lithium or valproate

  • Acute agitation in schizophrenia (injection only)

Vraylar vs. Geodon Pros and Cons

Vraylar

Vraylar carries the same class-wide boxed warning for mortality risk in elderly dementia patients, but avoids the added QT-prolongation warnings tied to Geodon. As a newer, brand-only drug, it costs more out-of-pocket with no generic option yet.

Pros

  • Approved for four separate conditions, including add-on treatment for MDD

  • Can be taken with or without food

  • No specific QT-prolongation warning, unlike Geodon

  • Approved for adolescents with schizophrenia and bipolar mania

Cons

  • No generic version available, so it stays a brand-only cost

  • Long half-life means side effects can take weeks to resolve after stopping

  • Higher akathisia rates in bipolar mania and MDD trials, up to 23%

  • No injectable option for acute agitation

Geodon

Geodon has been on the market since 2001 and is now available generically, giving it a longer track record and easier access. It requires closer heart-rhythm monitoring and must be taken with a substantial meal for proper absorption.

Pros

  • Available as a generic (ziprasidone), often cheaper than brand-only options

  • Over two decades of real-world clinical use since its 2001 approval

  • Available as a short-term injectable for acute agitation

  • Approved for bipolar maintenance combined with lithium or valproate

Cons

  • Carries specific warnings for QT-prolongation and torsade de pointes risk

  • Must be taken with a substantial meal for proper absorption

  • Not approved for adolescents or as an MDD add-on treatment

  • Risk of DRESS syndrome noted in labeling

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.